苯达莫司汀
美罗华
医学
切碎
内科学
肿瘤科
淋巴瘤
作者
Ian W. Flinn,Richard van der Jagt,Brad S. Kahl,Peter Wood,Tim E. Hawkins,David MacDonald,Mark Hertzberg,Yiu‐Lam Kwan,David Simpson,Michael Craig,Kathryn S. Kolibaba,Samar Issa,Regina Clementi,Doreen M. Hallman,Mihaela Munteanu,Ling Chen,John M. Burke
出处
期刊:Blood
[American Society of Hematology]
日期:2014-03-04
卷期号:123 (19): 2944-2952
被引量:553
标识
DOI:10.1182/blood-2013-11-531327
摘要
Key Points The complete response rate for first-line bendamustine/rituximab was statistically noninferior to R-CHOP or R-CVP in indolent NHL or MCL. The safety profile of bendamustine/rituximab is distinct from that of R-CHOP/R-CVP.
科研通智能强力驱动
Strongly Powered by AbleSci AI